Treatment of non-small cell lung cancer with EGFR-TKI
10.3760/cma.j.issn.1673-422X.2019.02.010
- VernacularTitle:非小细胞肺癌的EGFR-TKI治疗
- Author:
Lili LONG
1
;
Yanling LIANG
;
Xingmei ZHANG
;
Yusheng SHI
Author Information
1. 南方医科大学第一临床医学院
- Keywords:
Carcinoma,non-small-cell lung;
Receptor,epidermal growth factor;
Molecular targeted therapy;
Epidermal growth factor receptor-tyrosine kinase inhibitors;
Drug resistance
- From:
Journal of International Oncology
2019;46(2):105-108
- CountryChina
- Language:Chinese
-
Abstract:
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are the key to the treatment of advanced non-small cell lung cancer (NSCLC),but there are various drug-resistant mutations in the latter stage.The first and second generation of EGFR-TKIs significantly prolong the survival of patients with EGFR-activated mutant tumors.The third generation of EGFR-TKIs effectively inhibit the progress of T790M mutant tumors.The fourth generation of EGFR-TKIs inhibit both L858R,T790M and L858R,T790M,C797S mutant tumors.Using circulating tumor DNA and exogenous RNA can effectively detect the mutation types of EGFR,and choose EGFR-TKIs therapy or combined chemotherapy according to the mutation types.
